This round of financing will be mainly used to promote clinical trials and preclinical development of several projects of Akono R&D pipeline and expand international business cooperation.
Aikeno was founded at the end of 20 17, and the company was established in Bio-Nano Park of Suzhou Industrial Park. By focusing on the independent research and development of the inflammatory circuit of cell death, Acknowledgment has obtained many patents from China and the United States, and has global interests in the product pipeline. A large number of studies have shown that regulatory cell death plays a key role in many major diseases, so drugs targeting the inflammatory circuit of cell death may become platform drugs.
The company is developing a variety of potential FIC small molecule drugs for inflammatory diseases, fibrotic diseases, autoimmune diseases and tumors to meet the huge clinical needs. RIPK 1 IND, the fastest-growing product in the company's pipeline, has been approved by FDA and is about to start clinical trials.
Iacono's core team has more than 10 years of research experience in the biological mechanism and chemical transformation of cell death. The founder and CEO is Dr. Zhang Xiaohu, who has many years of experience in industrial drug research and development. He once worked in NeurocineBiosciences and served as the executive director of BioDuro/PPD, a leading CRO company, and successfully promoted many products to clinic.
Why did Dr. Sudan, as a co-founder and scientific consultant, participate in the research on the biological mechanism of cell death in Southwest Medical Center of the University of Texas and Beijing Institute of Life Sciences, and successively served as PI of Suzhou University and Suzhou Institute of System Medicine, and published many important biological research results, which were widely cited by peers?
Dr. Zhang Xiaohu, co-founder and CEO of Acknowledgment, said: Acknowledgment team abides by the promise of people who love science to protect your health, and is patient-centered and based on scientific innovation to develop new drugs for autoimmune and major diseases in tumor field. The company has established an efficient and professional R&D team and developed a number of pipelines with global intellectual property rights. The self-developed small molecule RIPK 1 inhibitor has been approved for clinical use in the United States, and many innovative projects are in the pre-clinical stage of IND/ KLOC. Thanks to the help and companionship of the old shareholder Chen Xing Venture Capital for many years, and thanks to the trust and support of the new shareholders Hongtai Fund, Zhongnan Venture Capital, Shenzhen Venture Capital, Yuanhe Holdings, Guangfa Shunde and Sanhua Hongdao. This round of financing will help Akeno to a new level and complete the transformation from R&D to clinical company.
Ms. thomas lee, a medical partner of Hongtai Fund, said: There are still huge clinical unmet needs of autoimmune diseases in the world, and small molecule drugs with brand-new mechanisms have always been the' bridgehead' for the research and development of new autoimmune drugs in the world. Iacono's team has a deep understanding of cell death pathways and potential related indications. Based on top-notch original basic biology research and solid transformation research, Iacono has independently developed a number of potential "platform drugs". Since its establishment four years ago, Acknowledgment has demonstrated a very practical and dedicated background of new drug research and development and efficient implementation. Hongtai Fund is optimistic about the development of Akeno. I am very happy to participate in the investment of Aikeno as the leader of this round, and look forward to the in-depth cooperation with Aikeno in the future, and continue to help the development and growth of Aikeno.
Wei Yufa, a partner of Zhongnan Venture Capital Fund, said: Akeno Bio focuses on the research and development of scarce target drugs, and the innovation value of R&D pipeline is extremely high. At the same time, it provides better therapeutic drugs for patients with huge unmet clinical needs. Acknowledgment's R&D team has been deeply involved in the field of innovative drugs for many years and accumulated rich development experience. We are very optimistic about the R&D ability and execution ability of the Akeno team, and look forward to the continuous breakthrough of Akeno Bio in the field of new drug research and development in the future, bringing good news to patients.
Dr Zhang Xiao, a partner of Yi Kai Capital, said: As we all know, regulatory cell death plays a key role in many important diseases. As one of the leading companies in the field of cell death regulation, we are very optimistic about the company's profound biological accumulation, rich transformation ability and the potential of its products to evolve into platform drugs in the future. Team Yi Kai is honored to help Akeno complete this round of financing, and looks forward to more breakthroughs in the near future to solve the vast unmet clinical needs.
enclose herewith
For more project information, please visit.